Puma Biotechnology Stock News

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By 5

Wall Street brokerages forecast that Puma Biotechnology, Inc. (NASDAQ:PBYI) will announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Puma Biotechnologys earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at $0.00. Puma Biotechnology reported earnings of []

Cubist Systematic Strategies LLC raised its position in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 162.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,694 shares of the biopharmaceutical companys stock after acquiring an additional 32,612 shares during the period. Cubist Systematic []

Puma Biotechnology Inc (NASDAQ: PBYI ) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH R132H mutation-negative. In the intent-to-treat population, progression-free survival (PFS) was not significantly longer with neratinib (median 6.0 months) versus the control arm (median 4.7 months). Also, there was no significant improvement Full story available on Benzinga.com

Puma Biotechnology Inc (NASDAQ: PBYI) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH R132H mutation-negative.  In the

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present data from the neratinib arm of the Phase II INSIGhT Trial at the 2021 Society for Neuro-Oncology Annual Meeting (SNO),

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Sy

Brokerages expect that Puma Biotechnology, Inc. (NASDAQ:PBYI) will post earnings of ($0.11) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Puma Biotechnology’s earnings, with the highest EPS estimate coming in at $0.00 and the lowest estimate coming in at ($0.21). Puma Biotechnology reported earnings of ($0.38) […]

Puma Biotechnology Inc. (NASDAQ:PBYI) price closed lower on Monday, November 15, dropping -1.08% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

The HER2 Inhibitors report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2028. The data included

Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q3 2021 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 4, 2021, following the

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted in Sept. 2021 to six non-executive employees, as required under Nasdaq Listing Rule 5635(c)(4).